GSK CEO dismisses rumors of AstraZeneca takeover

05/21/2008 | Reuters · Wall Street Journal (free content), The

Buying AstraZeneca could cause antitrust problems and does not fit GlaxoSmithKline's acquisition strategy, outgoing CEO Jean-Pierre Garnier said at a meeting Wednesday. Such a deal also would weaken research and development productivity because GSK has a stronger pipeline of new drugs than AstraZeneca, Garnier said. A spokesman for AstraZeneca said the company is expected to deliver an average of two treatments per year to market from 2010 onward.

View Full Article in:

Reuters · Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX